

# **HHS Public Access**

Author manuscript *Vaccine*. Author manuscript; available in PMC 2022 January 06.

Published in final edited form as: *Vaccine*. 2016 November 11; 34(47): 5777–5784. doi:10.1016/j.vaccine.2016.09.056.

# Improving hepatitis B birth dose in rural Lao People's Democratic Republic through the use of mobile phones to facilitate communication

Anonh Xeuatvongsa, MD, PhD<sup>a</sup>, Siddhartha Sankar Datta, MD, MPH<sup>b</sup>, Edna Moturi, MBBS<sup>c,d,1</sup>, Kathleen Wannemuehler, PhD<sup>c</sup>, Phanmanisone Philakong, MD<sup>b</sup>, Viengnakhone Vongxay, MD, MPH<sup>e</sup>, Vansy Vilayvone, MD, MPH<sup>e</sup>, Minal K. Patel, MD<sup>c,\*</sup>

<sup>a</sup>National Immunization Program, Mother and Child Health Center, Lao People's Democratic Republic Ministry of Health, Simuang Road, Vientiane, Lao Democratic People's Republic

<sup>b</sup>WHO Representative Office in Laos, 125 Saphanthong Road, Unit 5, Ban Saphanthongtai, Sisattanak District, Vientiane, Lao Democratic People's Republic

<sup>c</sup>Global Immunization Division, Centers for Disease Control and Prevention, 1600 Clifton Road, NE, Atlanta, GA 30329, United States

<sup>d</sup>Epidemic Intelligence Service, Centers for Disease Control and Prevention, 1600 Clifton Road, NE, Atlanta, GA 30329, United States

<sup>e</sup>Faculty of Postgraduate Studies, University of Health Sciences, Lao People's Democratic Republic Ministry of Health, Samsenthai Road, Vientiane Capital, Lao Democratic People's Republic

# Abstract

**Background:** Hepatitis B vaccine birth dose (HepB-BD) was introduced in Lao People's Democratic Republic to prevent perinatal hepatitis B virus transmission in 2008; high coverage is challenging since only 38% of births occur in a health facility. Healthcare workers report being unaware of home births and thus unable to conduct timely postnatal care (PNC) home visits. A quasi-experimental pilot study was conducted wherein mobile phones and phone credits were provided to village health volunteers (VHV) and healthcare workers (HCWs) to assess whether this could improve HepB-BD administration, as well as birth notification and increase home visits.

**Methods:** From April to September 2014, VHVs and HCWs in four selected intervention districts were trained, supervised, received outreach per diem for conducting home visits, and received mobile phones and phone credits. In three comparison districts, VHVs and HCWs were

<sup>1</sup>Present address: United Nations High Commissioner for Refugees, P.P. Box 2666, Dar Es Salaam, Tanzania. Conflicts of interest

Corresponding author. hgo9@cdc.gov (M.K. Patel).

Authors declare that they have no conflicts of interest.

Disclaimer

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Appendix A. Supplementary material

Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.vaccine.2016.09.056.

trained, supervised, and received outreach per diem for conducting home visits. A post-study survey compared HepB-BD coverage among children born during the study and children born one year before. HCWs and VHVs were interviewed about the study.

**Findings:** Among intervention districts, 463 study children and 406 pre-study children were enrolled in the survey; in comparison districts, 347 study children and 309 pre-study children were enrolled. In both arms, there was a significant improvement in the proportion of children reportedly receiving a PNC home visit (intervention p < 0.0001, comparison p = 0.04). The median difference in village level HepB-BD coverage (study cohort minus pre-study cohort), was 57% (interquartile range [IQR] 32–88%, p < 0.0001) in intervention districts, compared with 20% (IQR 0–50%, p < 0.0001) in comparison districts. The improvement in the intervention districts was greater than in the comparison districts (p = 0.0009).

**Conclusion:** Our findings suggest that the provision of phones and phone credits might be one important factor for increasing coverage. However, reasons for improvement in both arms are multifactorial and discussed.

#### Keywords

Postnatal visits; Lao PDR; Hepatitis B; Lay health worker; Mobile phones

## 1. Introduction

Globally, approximately 240 million people have chronic hepatitis B virus (HBV) infection; an estimated 600,000 die from its complications yearly [1,2]. Perinatal transmission plays a significant role in the development of chronic infection; infants infected during the first year of life have a 90% chance of developing chronic infection [3]. Hepatitis B vaccine birth dose (HepB-BD), recommended for all newborns within 24 h of birth, with at least 2 additional doses of hepatitis B vaccine, are 85–90% effective in preventing perinatal transmission [4,5]. It is challenging to achieve high HepB-BD coverage in many countries, since many newborns are born at home and lack access to timely vaccination.

An estimated 8% of the Lao People's Democratic Republic (Lao-PDR) population has chronic HBV infection [6]. Since 2008, Lao-PDR's national policy is to provide HepB-BD to all newborns within 7 days of birth, preferably providing it within 24 h of birth. In 2014, 50% of newborns received HepB-BD [7]. One challenge to achieving high coverage is that only 38% of births occur in a health facility; furthermore, 2011–2012 data show that only 38% of mothers and newborns received a health check at delivery or a postnatal care (PNC) check within 2 days of birth [8].

One way to improve HepB-BD coverage is to improve access to healthcare services, specifically PNC outreach services, whereby a mother and newborn receive life-saving interventions such as a medical examination; education on early and exclusive breastfeeding and clean cord care; Vitamin A, folate, and iron administration for the mother; and vaccination of the newborn, including HepB-BD. In Lao-PDR, one reason anecdotally reported by healthcare workers (HCWs) for suboptimal PNC outreach is lack of awareness of imminent deliveries or recent births. Some village health volunteers (VHVs) use their

personal phones to notify HCWs of births. However, reporting of births is sporadic, dependent on VHVs' awareness of a birth, access to a functional phone, ability to afford making a call, and awareness about what events should be communicated to HCWs. Mobile phones have been used in multiple settings to improve access to care, but few evaluations have been done to assess their health impact [9–15]. Despite limited evidence, a policy paper recommends providing mobile phones to community health workers to improve access to care [16].

To understand if mobile phones could improve access to care, a pilot study was conducted in Lao-PDR, in which mobile phones and phone credits were provided to VHVs and HCWs in intervention districts during April-September 2014, to assess the impact on HepB-BD coverage; secondary impact on timely birth notification and PNC home visits was also evaluated.

### 2. Methods

#### 2.1. Pilot study overview

The study design was a quasi-experimental design where the intervention was district-level non-random assignment, similar to a previous pilot where HepB-BD was stored outside the cold chain [17]. The design included a control group, and an evaluation of a cohort of children born before the study. Because of low reported HepB-BD coverage (reported administrative coverage in 2011: 2–15%), three districts (Ngoy, Nambark, and Phoukhoun) in Luang Prabang province and one district (Parklai) in neighboring Xayabuly province were selected to participate in the 6-month study. Three other districts (Phonxay, Chomphet, and Viengkham) in Luang Prabang and one district (Xienghone) in Xayabuly were chosen as comparison districts because of similar birth rates and reported HepB-BD coverage (reported administrative coverage in 2011: 2–13%). These districts are rural, located in the northern part of the country. In 2011, the intervention districts had 5083 births, while the comparison districts had 4236 births. Only health centers (HCs) with a functional cold chain (needed for vaccine storage) were enrolled. All intervention and comparison villages in the catchment area of the enrolled HCs were enrolled unless there was no VHV; in the intervention arm, villages were excluded if the VHV could not charge a phone or the village lacked network coverage.

The catchment area of the enrolled HCs consisted of 4–16 villages. Villages were classified as fixed, outreach, or mobile, depending on travel time and distance between the HC and village. Fixed villages had a HC within the village or one located a few kilometers away. Outreach villages were further from a HC, but HCWs could make a roundtrip visit in one day. Mobile villages were far from HCs, requiring HCWs to stay overnight during visits. [16]

**2.1.1. Intervention districts**—VHVs and HCWs received a one-day training on when VHVs should call HCWs (imminent delivery, mother/baby with danger signs, birth notification), what PNC services HCWs should provide, how HCWs should administer HepB-BD, and how to use the phones provided. One trained VHV from every enrolled village and every HC received a phone and US \$6 of phone credit monthly to facilitate

communication between the VHV and HC. To cover the cost of conducting outreach, standard government per diem (US \$5) was provided to HCWs for each home birth they attended and PNC home visit conducted.

**2.1.2. Comparison districts**—VHVs and HCWs received identical training provided in the intervention districts except training on phones. These staff were not provided with mobile phones or credits, but they were given identical per diem for each home visit.

#### 2.2. Household evaluation survey

From October to December 2014, an evaluation survey was conducted, using similar methods to a pilot to improve HepB-BD coverage among health facility births, where data on children born before the study (12–21 months of age, considered the baseline) and on children born during the intervention (0–9 months of age) were collected [17]. The survey was designed to evaluate the difference in the change in HepB-BD coverage between intervention and comparison districts. A sample size of 14 villages per arm had a 90% power to detect a difference of 10% in HepB-BD coverage between the intervention and comparison arms, with an estimated standard deviation of 0.10 and a significance level (alpha) of 0.05, using a two-sided Wilcoxon test assuming that the actual distribution was normal. This was inflated to 18 villages per access strata (fixed, outreach, mobile) to account for attrition due to poor access or lack of births.

In this stratified cluster survey, we defined three access strata because we expected access to affect improvement. Intervention HCs served 16 fixed, 52 outreach, and 71 mobile villages; comparison HCs served 13 fixed, 36 outreach, and 29 mobile villages. Three mobile intervention villages were  $\geq$ 360 min away from their respective HCs and were excluded. In the first stage of sampling, 18 villages (or all villages if <18) were chosen per stratum by systematic random sampling. In each village, all children born between April 1, 2013-September 30, 2013 (pre-study cohort) and between April 1, 2014-September 30, 2014 (study cohort) were eligible. (Supplemental Fig. 1)

In each village, enumerators conducted a census of all age-eligible children born during the study and born one year prior to the study, including age-eligible deceased children. For each eligible child, consenting caregivers were administered a questionnaire, which collected demographic data, birth and PNC details, and documented vaccination history. After completing the interviews, teams reviewed vaccination registers at the villages' primary HCs to obtain vaccination data on all children identified, as well as age-eligible children who were missed. Children without any documented vaccination data were assumed unvaccinated.

#### 2.3. VHV and HCW evaluation survey

VHVs and HCWs servicing the selected villages were interviewed with a structured questionnaire at the end of the study to understand practices and challenges. Interviewers asked the respondent open-ended questions and classified answers into pre-defined categories; if their answer was unable to be categorized, the full answer was noted.

#### 2.4. Data analysis

Data were entered and stored in a CSPro v5.0 database (Washington, DC) and analyzed in SAS v9·3 (Cary, NC). During data cleaning, if vaccination dates by register and card were discrepant, registers were considered more accurate. Weights accounting for the selection probability of villages within each stratum were calculated and applied to all results except for basic demographics. Proportions were calculated for various demographic and population characteristics by cohort and arm. HepB-BD was defined as any dose given within 30 days of life. Children who died on day of life 0 or 1 were excluded. Change in village-level HepB-BD coverage was estimated by subtracting coverage in children born one year before the study from children born during the study by village. For the village-level analysis, to assess change in HepB-BD coverage, only villages with  $\geq 1$  child in each age cohort were analyzed. Within arms, non-parametric Wilcoxon sign-rank test was used to test whether change in village BD coverage was significantly different from zero. At the villagelevel, to test the difference in the median change in HepB-BD coverage between intervention and control arms, non-parametric Wilcoxon two-sample test was used. At the individual child-level, secondary analyses were performed (e.g. factors related to HepB-BD receipt); we accounted for village-level clustering using survey methods and report the second-order Rao-Scott  $\chi^2$  p-values. For analysis of the VHV and HCW surveys, proportions were calculated based on the pre-defined categorization described above; Fisher p-values were calculated because of small sample size.

#### 2.5. Human subjects' rights and ethics

We obtained informed consent from caregivers. Study protocol was approved by the Lao-PDR Ministry of Health and the Ethics Review Committee at the WHO Regional Office for the Western Pacific. CDC determined this activity was not human subjects' research.

#### 3. Results

#### 3.1. Pilot study implementation

In the intervention arm, 17 of 21 HCs had a functional cold chain; HCWs from these HCs and VHVs from 139 villages were trained as described. In the comparison districts, 13 of 25 HCs had a functional cold chain; HCWs from these HCs and VHVs from 78 villages were trained as described. No HCs in Chomphet District had a functional cold chain; thus, only 3 comparison districts were included. Six enrolled HCs (3 intervention, 3 comparison) reported HepB-BD vaccine shortages during the study.

#### 3.2. Household evaluation survey

In the intervention arm, 51 villages (16 fixed, 18 outreach, and 17 mobile) were visited; one selected mobile village was excluded because there were no eligible children in either age cohort. In this arm, 465 children aged 0–9 months and 406 children aged 12–21 months were identified. In the comparison arm, 49 villages (13 fixed, 18 outreach, and 18 mobile) were visited; 349 children aged 0–9 months and 309 children aged 12–21 months were identified. There were a median of 12 (IQR 7–21) age-eligible children in the intervention villages; there were a median of 12 (IQR 7–16) age-eligible children in the comparison

villages. There were two refusals, one (0.3%) in each age cohort, in the comparison arm; vaccination data were available in the EPI register, so these two children were included in the vaccination analysis.

At baseline, intervention and comparison pre-study children were different with respect to religion, ethnicity, maternal education, and HepB-BD receipt (Table 1). Among them, 95 (15%) of 406 in intervention villages had received HepB-BD compared with 135 (39%) of 309 in comparison villages (p = 0.001).

Improvement was seen in heath facility delivery rates during the study. In the intervention arm, children born during the study were more likely to be born in a health facility than pre-study children (p = 0.003); the comparison had no change in health facility birth rates (p = 0.26) (Table 1). In both arms, there was a significant improvement in the proportion of children reportedly receiving a PNC home visit during the study versus pre-study (intervention p < 0.0001, comparison p = 0.04) (Table 1).

To compare change in village HepB-BD coverage, two intervention villages (1 fixed, 1 mobile) and five comparison villages (1 fixed, 4 outreach) were excluded as children were only identified in one cohort precluding change calculation. In the intervention arm, pre-study median village HepB-BD coverage was 0% (IQR 0–20%); study median village HepB-BD was 75% (IQR 57–100%) (Fig. 1). In the comparison arm, pre-study median village HepB-BD coverage was 37% (IQR 0–87%); study median village HepB-BD was 82% (IQR 50–100%) (Fig. 1). In the intervention arm, median change in village HepB-BD coverage was 57% (IQR 32–88%, Signed Rank p < 0.0001) compared with median change of 20% (IQR 0–50%, Signed Rank p < 0.0001) in the comparison (Wilcoxon two-sample test p-value = 0.0009) (Fig. 1). There was no significant difference in median change in Bacillus Calmette-Guérin vaccination between arms (data not shown, Wilcoxon p = 0.79).

At the child-level, HepB-BD coverage improved in both arms over time (Table 1); factors related to HepB-BD receipt were analyzed. In both arms, HepB-BD coverage improved significantly among both home and health facility births during the study, with higher coverage among children born in health facilities than at home in all four groups (Table 2). HepB-BD coverage also improved among children who reportedly received and did not receive a PNC home visit. Significantly more intervention study children received a HepB-BD if they had a PNC home visit compared to those that did not report a visit (p = 0.003). Compared with pre-study children, study children had a higher HepB-BD coverage in all access strata (Table 2, Supplemental Fig. 2). A sub-analysis was done among home births (where PNC outreach was assumed to have its greatest impact); similar improvements were seen regardless of access strata and receipt of a PNC home visit (Table 3).

#### 3.3. HCW survey

Seventeen intervention HCWs and 13 comparison HCWs were interviewed. All HCWs reported it was important to visit a newborn within 24 h of birth. Only 10 (59%) intervention HCWs and 9 (69%) comparison HCWs reportedly provided HepB-BD to all newborns. All intervention HCWs and 11 (85%) comparison HCWs reportedly were notified by VHVs of imminent deliveries or births. In the intervention arm, all reported notifications were by

mobile phone; in the comparison, 8 (73%) of the 11 reporting notification stated they were notified by mobile phone (Fisher p = 0.05). In both arms, there were challenges to visiting a home within 24 h of notification, with village inaccessibility being reported most frequently. (Table 4)

#### 3.4. VHV survey

Fifty-two intervention VHVs and 49 comparison VHVs were interviewed. In both arms, 76–83% reportedly informed HCWs about imminent deliveries/births most or all of the time. In the intervention arm, 43 (83%) VHVs reported informing HCWs either during labor or within 1 day of birth compared to 32 (65%) comparison VHVs. In the intervention arm, 43 (96%) used the study-provided mobile phone; in the comparison, 37 (84%) used their own mobile phone. Forty (89%) intervention and 23 (62%) VHVs reported no phone problems (Fisher p = 0.008). Lack of phone credit was reported by 4 (9%) intervention VHVs and 13 (35%) comparison VHVs.

## 4. Discussion

The purpose of this study was to ascertain if the provision of a mobile phone and phone credits, along with training and outreach per diem, could improve timely birth notification by VHVs to HCWs, as an intermediate step to increasing PNC home visits and HepB-BD administration. A significant improvement in HepB-BD coverage was seen in both arms, with a greater improvement seen in the intervention arm; our interpretation of this is that the provision of phones and credits was an important factor to increase coverage, along with training and regular outreach per diem. This was unexpected, as mobile phones are common in Lao-PDR; 84% of comparison VHVs used their own mobile phone to notify HCW. Some insight can be gained from the VHV survey where comparison VHVs reported more problems with mobile phones, specifically a lack of phone credits, that might have contributed to fewer notifications; lack of credits has been identified as a challenge elsewhere [18]. Furthermore, providing a phone to intervention VHVs might have been an incentive for them to actively participate in this study; increased motivation, increased community credibility, and increased empowerment from receiving a phone have been seen previously [10,19–21].

Our intervention was targeted at improving PNC home visits and HepB-BD coverage among children born at home. However, an unexpected increase in HepB-BD coverage among health facility births was seen, probably because of training and increased monitoring; neither outreach per diem nor phones should improve health facility vaccination [22–24]. However, not all health facility-born children received HepB-BD; possible reasons could include vaccine stockout or HCW apathy, competing workload, forgetfulness, or misperceptions of false contraindications. Further improvements are needed to ensure all health facility-born children receive HepB-BD.

HepB-BD coverage improvement in this study among home births was probably multifactorial, a combination of increased notification because of VHV education in both arms, mobile phone provision in the intervention arm, improved HCW knowledge, increased PNC visits due to increased notification and per diem, and the Hawthorne effect. However,

we could not separate out the relative role of these different factors, since data were not collected on the number of notifications, the HCW response, and what was provided at the PNC visit. As expected, among home births, access affected a child's HepB-BD status, as has been seen previously in Lao-PDR [17]. Unfortunately, health service access cannot be quickly changed; however, a dramatic improvement in HepB-BD coverage was seen in both arms in all access strata. Further improvements are still needed, most easily accomplished in the fixed villages, as these newborns are easy for HCWs to visit and vaccinate.

We expected that increased birth notifications would lead to increased PNC home visits and, in turn, to increased HepB-BD coverage. There was a statistically significant improvement in reported PNC visits in both arms, but among home births, a PNC visit was associated with HepB-BD receipt only in the intervention arm during the study. A significant association in the comparison was not seen, but this could have been due to insufficient power.

This study has several limitations. Findings might not be generalizable. The quasiexperimental design relied on administrative data to select comparable control districts; however, the survey found that the intervention and control populations were different at baseline. This makes inference regarding observed differences challenging. Some villages had 100% coverage at baseline and therefore no further improvement could be expected; this was more frequent in the comparison and could have skewed the findings. Several selected villages only had children from one age group, making comparison impossible. Some villages only had a small number of eligible children; small changes in the number of children born and vaccinated could lead to large changes in coverage. Use of the non-parametric statistical tests ameliorated this issue's impact. The survey identified more children in the younger cohort which might mean older children were missed, since there was no evidence of a changing birth rate; these missed children could not be accounted for. Additionally, some secondary analyses had small sample sizes and were potentially under-powered to detect a difference. We cannot account for the impact of the Hawthorne effect. Recall bias could affect responses. Documented vaccination data were not available for 3% of children.

Scaling up this pilot could improve HepB-BD coverage in Lao-PDR. However, while provision of phones improved coverage, this could be costly. Comparison VHVs had phones, but insufficient phone credits; a more cost-effective approach might be to provide VHVs with credits. This intervention provided a platform to integrate other mother and child health service interventions, so an integrated program with cost-sharing could be considered. Scale-up of some or all of the interventions implemented in this study could lead to decreased chronic HBV infection. Furthermore, more home visits will enable HCWs to provide additional PNC services that could improve other health indicators. Future research is needed to understand driving factors in the provision of PNC home visits and HepB-BD, especially among home births.

# **Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

### Acknowledgements

We are thankful to all the village health volunteers, healthcare workers, district, provincial, and national public health staff who participated in this work and the parents and children of the surveyed villages who agreed to be part of this survey, without which this important activity would not have been a reality. We would also like to thank Alicia Ruiz, Eric Wiesen, Keith Feldon, and Alejandro Ramirez-Gonzalez for their support. We would like to thank the World Health Organization for funding this work.

#### Role of the funding source

Funding for this survey was provided by WHO; WHO Lao-PDR office staff supported the Ministry of Health in implementation and interpretation of results.

#### References

- Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012;30:2212–9. [PubMed: 22273662]
- [2]. Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005;34:1329–39. [PubMed: 16249217]
- [3]. Edmunds WJ, Medley GF, Nokes DJ, Hall AJ, Whittle HC. The influence of age on the development of the hepatitis B carrier state. Proc Biol Sci 1993;253:197–201. [PubMed: 8397416]
- [4]. Hepatitis B vaccines: WHO position paper-recommendations. Vaccine 2010;28:589–90. [PubMed: 19896455]
- [5]. Van Damme P, Ward J, Shouval D, Wiersma S, Zanetti A. Hepatitis B vaccines. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. China: Elsevier Saunders; 2013.
- [6]. World Health Organization Regional Office for the Western Pacific. Western Pacific Regional Plan for Hepatitis B control through immunization. Manila (Philippines); 2007. http:// www.wpro.who.int/immunization/documents/docs/POA\_HepB.pdf [March 17, 2016].
- [7]. Lao People's Democratic Republic Ministry of Health. WHO-Unicef joint reporting form; 2014. http://hiip.wpro.who.int/portal/Dashboards/Immunization/Immunizationdashboards/ TabId/169/ArtMID/905/ArticleID/76/Default [March 17, 2016].
- [8]. Lao People's Democratic Republic Ministry of Health, Lao Statistics Bureau. Lao social indicator survey 2011–12. Vientiane (Lao PDR); 2012. http://dhsprogram.com/pubs/pdf/FR268/FR268.pdf [March 17, 2016].
- [9]. Noordam AC, Kuepper BM, Stekelenburg J, Milen A. Improvement of maternal health services through the use of mobile phones. Trop Med Int Health 2011;16:622–6. [PubMed: 21342374]
- [10]. Agarwal S, Perry HB, Long LA, Labrique AB. Evidence on feasibility and effective use of mHealth strategies by frontline health workers in developing countries: systematic review. Trop Med Int Health 2015;20:1003–14. [PubMed: 25881735]
- [11]. Ngabo F, Nguimfack J, Nwaigwe F, Mugeni C, Muhoza D, Wilson DR, et al. Designing and implementing an innovative SMS-based alert system (RapidSMS-MCH) to monitor pregnancy and reduce maternal and child deaths in Rwanda. Pan Afr Med J 2012;13:31. [PubMed: 23330022]
- [12]. Braun R, Catalani C, Wimbush J, Israelski D. Community health workers and mobile technology: a systematic review of the literature. PLoS ONE 2013;8: e65772. [PubMed: 23776544]
- [13]. Hall CS, Fottrell E, Wilkinson S, Byass P. Assessing the impact of mHealth interventions in lowand middle-income countries–what has been shown to work? Glob Health Action 2014;7:25606. [PubMed: 25361730]
- [14]. Lee SH, Nurmatov UB, Nwaru BI, Mukherjee M, Grant L, Pagliari C. Effectiveness of mHealth interventions for maternal, newborn and child health in low- and middle-income countries: systematic review and meta-analysis. J Glob Health 2016;6:010401. [PubMed: 26649177]

- [15]. Watterson JL, Walsh J, Madeka I. Using mHealth to improve usage of antenatal care, postnatal care, and immunization: a systematic review of the literature. Biomed Res Int 2015;2015:153402.
  [PubMed: 26380263]
- [16]. Africa Progress Panel. Maternal health: investing in the lifeline of healthy societies and economies; 2010. http://www.who.int/pmnch/topics/maternal/app\_maternal\_health\_english.pdf [March 17, 2016].
- [17]. Kolwaite AR, Xeuatvongsa A, Ramirez-Gonzalez A, Wannemuehle K, Vongxay V, Vilayvone V, et al. Hepatitis B vaccine stored outside the cold chain setting: a pilot study in rural Lao PDR. Vaccine 2016.
- [18]. Jennings L, Ong'ech J, Simiyu R, Sirengo M, Kassaye S. Exploring the use of mobile phone technology for the enhancement of the prevention of mother-to-child transmission of HIV program in Nyanza, Kenya: a qualitative study. BMC Public Health 2013;13:1131. [PubMed: 24308409]
- [19]. Medhi I, Jain M, Tewari A, Bhavsar M, Matheke-Fischer M, Cutrell E. Combating rural child malnutrition through inexpensive mobile phones. In: Proceedings of the 7th Nordic conference on human-computer interaction: making sense through design. Copenhagen (Denmark): ACM; 2012. , http://research.microsoft.com/pubs/170446/Medhi-NordiCHI2012-CommCareCasestudy.pdf [March 17, 2016].
- [20]. Chib A The Aceh Besar midwives with mobile phones project: design and evaluation perspectives using the information and communication technologies for healthcare development model. J Comput-Med Commun 2010;15:500–25.
- [21]. Little A, Medhanyie A, Yebyo H, Spigt M, Dinant GJ, Blanco R. Meeting community health worker needs for maternal health care service delivery using appropriate mobile technologies in Ethiopia. PLoS ONE 2013;8:e77563. [PubMed: 24204872]
- [22]. World Health Organization. Practices to improve coverage of the hepatitis B birth dose vaccine. Geneva (Switzerland): World Health Organization; 2012., http://apps.who.int/iris/bitstream/ 10665/78616/1/WHO\_IVB\_12.11\_eng.pdf [March 17, 2016].
- [23]. Djibuti M, Gotsadze G, Zoidze A, Mataradze G, Esmail LC, Kohler JC. The role of supportive supervision on immunization program outcome – a randomized field trial from Georgia. BMC Int Health Hum Rights 2009;9(Suppl 1):S11. [PubMed: 19828055]
- [24]. Uskun E, Uskun SB, Uysalgenc M, Yagiz M. Effectiveness of a training intervention on immunization to increase knowledge of primary healthcare workers and vaccination coverage rates. Public Health 2008;122:949–58. [PubMed: 18313703]

Xeuatvongsa et al.





Comparison of hepatitis B vaccine birth dose (HepB-BD) coverage by village among children born before and during the study in the intervention and comparison arms — Mobile Phone Pilot Study, Lao-PDR, 2014.

Characteristics of children participating in the final survey — Mobile Phone Pilot Study, Lao-PDR, 2014.<sup>a</sup>

	Interve	ention					Comp	arison				
	Pre-stu	$^{\rm h}$		During	the stu	ыdy <sup>c</sup>	Pre-st	$^{q}$		During	the stu	$dy^c$
-	Total	=	%	Total	=	%	Total	=	%	Total	=	%
Male	354	191	54	420	203	48	263	131	50	309	153	50
Ethnic group												
Lao	354	175	49	420	211	50	263	21	×	309	21	٢
Khmu	354	100	28	420	106	25	263	208	62	309	237	77
Hmong	354	71	20	420	96	23	263	28	11	309	38	12
Other	354	8	7	420	7	ы	263	9	7	309	13	4
Village classification												
Fixed	406	188	46	465	220	47	309	117	38	349	106	30
Outreach	406	150	37	465	153	33	309	80	26	349	112	32
Mobile	406	68	17	465	92	20	309	112	36	349	131	38
Deceased at time of survey	354	4	1	422	10	7	263	3	1	309	4	1
Highest level of maternal education completed												
None	351	65	19	419	55	13	262	52	20	309	62	20
Primary school	351	186	53	419	209	50	262	166	63	309	199	64
Secondary school or higher	351	100	28	419	155	37	262	44	17	309	48	16
Religion												
Buddhist	354	193	55	420	233	55	263	26	10	309	33	11
Animist	354	161	45	420	186	4	263	237	90	309	276	89
Christian	354	0		420	-	0	263	ī		309	ī	
Birth details <sup>d</sup>												
Born at health facility	350	169	39	413	241	52	260	123	42	308	156	47
Born at home with SBA	350	20	4	413	28	9	260	18	Ś	308	20	٢
Born at home without SBA	350	161	57	413	144	42	260	119	53	308	132	46
HCW made postnatal care visit to home <sup>d</sup>	353	62	11	418	132	30	260	57	19	308	88	28
Children with written vaccination data (card or revister) $d$	406	393	96	463	439	93	309	306	66	347	342	66

	Interv	ention					Compa	arison				
	Pre-st	$^{p}$		During	g the sti	$dy^{c}$	Pre-stu	$\mathrm{idy}^{b}$		During	the str	$\mathrm{dy}^{c}$
	Total	u	%	Total	u	%	Total	u	%	Total	u	%
Hepatitis B birth dose (≤30 days) <sup>d</sup>	406	95	15	463	348	70	309	135	39	347	257	71
HepB BD timing <sup>d</sup>												
0-1 day	95	63	74	348	287	81	135	114	83	257	232	90
2–7 days	95	29	54	348	55	17	135	14	11	257	22	6
8–30 days	95	3	19	348	9	7	135	7	9	257	ю	1
Bacillus Calmette-Guerin (BCG) <sup>4</sup>	406	381	94	463	400	84	309	295	96	347	314	90

 $a^2$  children born during the study in the intervention arm and 2 child born during the study in the comparison arm died on day of life 0 or 1 and are excluded as they were not eligible for vaccination. In each arm, denominators change as children were identified during the health facility vaccination record review who were not identified during the household visits. These age-eligible children are included as they were eligible for services from the health facility during the defined time periods.

 $b_{\rm Tre-study}$  = born one year prior to study implementation (12–21 month olds).

cDuring study = born during study implementation (0–9 month olds).

d Weighted percentages shown.

# Table 2

Selected factors associated with receipt of hepatitis B vaccine birth dose (HepB-BD) among children born before and during the pilot study in the intervention and comparison arms — Mobile Phone Pilot Study, Lao-PDR, 2014.

Xeuatvongsa et al.

	Interv	'ention						Comp	ırison					
	Born	pre-study		Born d	luring the stuc	ły	p Value	Born p	re-study		Born d	uring the stud	y	p Value
	Total	Received HepB-BD	%	Total	Received HepB-BD	%	comparing HepB-BD between those born pre-study to those born during the study	Total	Received HepB-BD	%	Total	Received HepB-BD	%	Comparing HepB-BD between those born pre-study to those born during the study
Birth location														
Health facility	169	60	29	241	208	82	<0.0001	123	88	71	156	147	95	0.0002
Home	181	26	×	170	111	59	<0.0001	137	25	16	150	81	50	<0.0001
p-Value comparing HepB-BD between health facility and home births			0.001			0.001				<0.0001			<0.0001	
PNC home visit														
Yes	62	26	34	132	118	86	<0.0001	57	24	38	86	64	70	<0.0001
None	291	62	14	284	203	64	<0.0001	203	89	39	220	164	72	0.009
p-Value comparing HepB-BD between those receiving and those not receiving a PNC visit			0.06			0.003				0.89			0.92	
Village classification														
Fixed	188	74	39	220	181	82	<0.0001	117	60	51	106	76	92	<0.0001
Outreach	150	15	10	151	109	72	<0.0001	80	15	19	110	53	48	0.0003
Mobile	68	9	6	92	58	63	<0.0001	112	60	54	131	107	82	0.0001
p-value comparing HepB-BD between the three village classifications			0.02			0.13				0.01			0.0003	

Vaccine. Author manuscript; available in PMC 2022 January 06.

Bold values indicate a statistically significant p value ( $\leq 0.05$ ).

Author Manuscript

# Table 3

Selected factors associated with receipt of hepatitis B vaccine birth dose (HepB-BD) among children born at home before and during the pilot study in the intervention and comparison arms — Mobile Phone Pilot Study, Lao-PDR, 2014.

Xeuatvongsa et al.

	Interv	ention						Comp	ırison					
	Born p	ore-study		Born d	uring the stud	v	p Value comparing	Born p	re-study		Born d	aring the study		p Value comparing
	Total	Received HepB-BD	%	Total	Received HepB-BD	%	nepbbJ Detween those born pre- study to those born during the study	Total	Received HepB-BD	%	Total	Received HepB-BD	%	neppBJ Detween those born pre- study to those born during the study
PNC home visit														
Yes	24	6	36	65	57	84	0.0002	37	6	22	62	43	65	0.002
None	156	17	9	104	53	41	0.0002	98	16	14	88	38	40	0.009
p-Value comparing HepB-BD between those receiving and those not receiving a PNC visit			0.09			0.001				0.44			0.11	
Village classification														
Fixed	68	19	28	65	50	LL	<0.0001	40	12	30	26	24	92	<0.0001
Outreach	68	5	٢	59	37	63	<0.0001	50	6	12	LL	26	34	0.005
Mobile	45	2	4	46	24	52	<0.0001	47	Ζ	15	47	31	<u>66</u>	<0.0001
p-Value comparing HepB-BD between the three village classifications			0.05			0.22				0.27			0.005	

Vaccine. Author manuscript; available in PMC 2022 January 06.

Bold values indicate a statistically significant p value ( $\leq 0.05$ ).

Healthcare worker (HCW) survey assessing the study implementation and postnatal care outreach provided — Mobile Phone Pilot Study, Lao-PDR, 2014.

Xeuatvongsa et al.

	Interve	ention $(n = 17)$	Comps	rison (n = 13)
	п	%	п	%
Knowledge				
Reported it was important to visit a baby within 24 h of birth	17	100	13	100
Knew optimal timing of HepB-BD is ≤24 h	15	88	10	ΓL
Notification				
Village health volunteers (VHVs) notify HCW of imminent deliveries/births	17	100	11	85
VHV notified HCW by mobile phone	17	100	8	73
Postnatalhomevisit				
% of the home births that HCW visited within 24 h of notification				
Never	0	0	0	0
25% of the time	7	41	3	23
50% of the time	1	9	3	23
75% of the time	-	9	-	8
Most of the time	8	47	4	31
All of the time	0	0	2	15
Problems preventing visiting home births within 24 h of notification				
Village too far	4	24	7	15
Village inaccessible	10	59	9	46
No outreach money	4	24	3	23
Too busy	0	0	7	15
Reportedly provide HepB-BD for all newborns	10	59	6	69
Services provided at a postnatal home visit				
${\operatorname{BCG}}^d$ vaccine for neonate	11	65	10	LT .
HepB-BD vaccine for neonate	17	100	11	85
Education on clean cord care	15	88	12	92
Education on exclusive breast feeding	17	100	12	92
Education on vaccine schedule	11	65	8	62
Vitamin A for mother	12	71	12	92

Author Manuscript

Author Manuscript

Author Manuscript

omparison (n = 13) % 85 77 92 92 12 12 94 94 16 16 <sup>a</sup>Bacillus Calmette-Guérin. Examined mother Examined baby